Ab­bott plots new paths to clin­i­cal tri­al di­ver­si­ty, join­ing bio­phar­ma push for broad­er in­clu­sion

Clin­i­cal tri­als have a di­ver­si­ty prob­lem. That’s the open­ing state­ment on Ab­bott’s new web­site to pro­mote its lat­est di­ver­si­ty ef­forts — and the rea­son why it’s lay­ing out con­crete steps for change.

While lack of di­ver­si­ty isn’t ex­act­ly shock­ing news in bio­phar­ma, the Covid-19 pan­dem­ic and resurg­ing racial in­equities over the past two years have pushed the is­sue to the fore­front with ad­vo­cates now hope­ful for re­al change.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.